Let’s Discuss Your Preclinical Imaging Requirements

From early candidate selection to efficacy, biodistribution, safety, and translational research, every decision in drug development depends on reliable in vivo data.

Bruker's integrated portfolio of MRI, PET, SPECT, micro-CT, and Optical Imaging solutions helps pharmaceutical, biotech, and CRO teams to:

• visualize biology non-invasively before changes become visible,
• monitor therapeutic & theranostic response longitudinally,
• generate deeper insights from every animal study that strengthen go/no-go decisions,
• demonstrate mechanism of action with greater confidence, and
• accelerate candidate selection, thus reducing development risk.

Whether you're evaluating small molecules, biologics, cell and gene therapies, radiopharmaceuticals, nanoparticles, or novel formulations, our imaging platforms provide the sensitivity, anatomical detail, and quantitative data needed to accelerate development with confidence.

Beyond scientific performance, Bruker's solutions are designed to maximize laboratory efficiency. High-throughput workflows, longitudinal imaging strategies, and multimodal data acquisition enable researchers to extract more information from fewer animals, reduce study timelines, and lower overall operating costs. The result is a reduced total cost of ownership while improving the quality and translational value of your data.